TrialClinical and translational science2026

Model-Informed Development of a Subcutaneous Formulation of Tislelizumab: Phase 1 Pharmacokinetics in Patients With Cancer.

Xiangyu Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.